BioCentury
ARTICLE | Company News

FDA delays TKTX's Dynepo

November 22, 2000 8:00 AM UTC

The FDA has required that data be provided on additional manufacturing runs of Dynepo gene activated human erythropoietin (GA-EPO) developed by Transkaryotic Therapies (TKTX) and Aventis (AVE) to trea...